ResearcherNagoya UniversityActive in the last 2 years
Mitsuru Tashiro
Matched on OpenAlex author ID A5113884289. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- A Case of Pancreatic Cancer Complicated by Active Pulmonary Tuberculosis Successfully Managed through a Multidisciplinary Treatment Strategy. Co-author DOI 10.70352/scrj.cr.26-0532↗
- Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Rec… Co-author DOI 10.1097/mpa.0000000000002446↗
- Clinical impact of additional therapy for residual pancreatic cancer. Co-author DOI 10.1007/s00595-019-01900-y↗
- Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14138↗
- Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.012↗
- Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6699-8↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasuhiro Kodera · 6 shared papers, 2018–2026 · strength 0.86
- Paper A Case of Pancreatic Cancer Complicated by Active Pulmonary Tuberculosis Successfully Managed through a Multidisciplina… DOI 10.70352/scrj.cr.26-0532↗
- Paper Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Na… DOI 10.1097/mpa.0000000000002446↗
- Paper Clinical impact of additional therapy for residual pancreatic cancer. DOI 10.1007/s00595-019-01900-y↗
- Fuminori Sonohara · 4 shared papers, 2018–2020 · strength 0.35
- Paper Clinical impact of additional therapy for residual pancreatic cancer. DOI 10.1007/s00595-019-01900-y↗
- Paper Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. DOI 10.21873/anticanres.14138↗
- Paper Biological and conditional factors should be included when defining criteria for resectability for patients with pancre… DOI 10.1016/j.hpb.2019.01.012↗
- Masamichi Hayashi · 4 shared papers, 2018–2020 · strength 0.35
- Paper Clinical impact of additional therapy for residual pancreatic cancer. DOI 10.1007/s00595-019-01900-y↗
- Paper Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. DOI 10.21873/anticanres.14138↗
- Paper Biological and conditional factors should be included when defining criteria for resectability for patients with pancre… DOI 10.1016/j.hpb.2019.01.012↗
- Suguru Yamada · 4 shared papers, 2018–2020 · strength 0.35
- Paper Clinical impact of additional therapy for residual pancreatic cancer. DOI 10.1007/s00595-019-01900-y↗
- Paper Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. DOI 10.21873/anticanres.14138↗
- Paper Biological and conditional factors should be included when defining criteria for resectability for patients with pancre… DOI 10.1016/j.hpb.2019.01.012↗
- Kenta Tanaka · 1 shared paper, 2026 · strength 0.29
- Mitsuro Kanda · 3 shared papers, 2019–2020 · strength 0.28
- Paper Clinical impact of additional therapy for residual pancreatic cancer. DOI 10.1007/s00595-019-01900-y↗
- Paper Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. DOI 10.21873/anticanres.14138↗
- Paper Biological and conditional factors should be included when defining criteria for resectability for patients with pancre… DOI 10.1016/j.hpb.2019.01.012↗
- Tomohisa Otsu · 1 shared paper, 2025 · strength 0.22
- Masahiro Nakatochi · 1 shared paper, 2025 · strength 0.22
- Nobuhiko Nakagawa · 1 shared paper, 2025 · strength 0.22
- Keizo Fujita · 1 shared paper, 2025 · strength 0.22
- Tsutomu Fujii · 2 shared papers, 2018–2020 · strength 0.17
- Masaya Suenaga · 2 shared papers, 2018–2020 · strength 0.16
- Yuki Sunagawa · 1 shared paper, 2020 · strength 0.09
- Yoshiyasu Kato · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.